Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
38.53
-1.10 (-2.78%)
At close: Apr 18, 2024, 4:00 PM
38.00
-0.53 (-1.38%)
Pre-market: Apr 19, 2024, 8:00 AM EDT
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CLDX stock have an average target of 66, with a low estimate of 27 and a high estimate of 90. The average target predicts an increase of 71.30% from the current stock price of 38.53.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CLDX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +107.63% | Apr 17, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $67 | Buy | Reiterates | $67 | +73.89% | Mar 22, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $72 → $90 | Strong Buy | Maintains | $72 → $90 | +133.58% | Feb 27, 2024 |
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 20, 2023 |
| Wells Fargo | Wells Fargo | Sell → Hold Upgrades $27 | Sell → Hold | Upgrades | $27 | -29.92% | Nov 10, 2023 |
Financial Forecast
Revenue This Year
3.21M
from 6.88M
Decreased by -53.32%
Revenue Next Year
2.81M
from 3.21M
Decreased by -12.45%
EPS This Year
-3.07
from -2.92
EPS Next Year
-3.15
from -3.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.8M | 6.8M | 6.8M | 210.0M | 661.5M |
| Avg | 3.2M | 2.8M | 3.3M | 85.6M | 393.0M |
| Low | n/a | n/a | n/a | n/a | 157.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.8% | 112.4% | 142.6% | 6,219.6% | 672.4% |
| Avg | -53.3% | -12.4% | 18.1% | 2,477.2% | 358.9% |
| Low | - | - | - | - | 83.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.89 | -1.85 | -1.85 | -2.36 | 2.94 |
| Avg | -3.07 | -3.15 | -4.01 | -3.01 | 0.81 |
| Low | -3.48 | -3.85 | -6.00 | -3.45 | -0.34 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.